Follow-up Care After Treatment for Endometrial Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-08-31

Study Completion Date

2010-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purposes of this study are to examine the needs (symptoms, support, information) and satisfaction of women during follow-up in the community after completing treatment for endometrial cancer. This information will be collected from the perspective of the women themselves, their primary care providers (family physician or gynecologist) and the health care providers (oncologist, nurses, social worker, psychologist) at the cancer centre.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Research Question How has this transfer in follow-up care impacted performance indicators?

* Volume of follow-up care transferred
* Percentage of women, who have required a re-entry consultation
* Fiscal implication of this transfer of follow-up care

Patient stakeholders:

* What are women's perceptions of the transition of follow-up care?
* What are women's supportive care needs during the transition of follow-up care and ongoing needs?

Primary Care Practitioner stakeholders:

* What are the primary care practitioners' perceptions of the process of transition of follow-up care?
* What are the primary care practitioners' educational needs?
* What are the primary care practitioners' perceptions of the process of re-entry for in women with suspected recurrence?

Tertiary Centre: Health care providers stakeholders

o What are the perceptions of tertiary health care providers about the transition of follow-up care?

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometrial Neoplasm

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Endometrial neoplasia Follow-up care survivorship Primary care provider

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

ECOLOGIC_OR_COMMUNITY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants- women diagnosed with endometrial cancer:

* 18 years of age or older.
* speak English or French
* who have been treated (surgery and/or radiation therapy) at TOH.
* who have been discharged from follow-up in the cancer centre in the past 6 months.
* Participants-primary care provider practitioner:

* providing follow-up care to at least one woman with endometrial cancer
* Participants- health care providers at the tertiary centre :

* physicians, nurses or allied health care providers whose primary responsibility are to provide care to women with gynecological cancer.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Ottawa Hospital

Ottawa, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2008361-01H for OHREB

Identifier Type: -

Identifier Source: secondary_id

OHRI 2008-361